HIGHLIGHTS
SUMMARY
"In vitro" and "in_vivo" models using HTB-9 UBC cells confirmed chemotherapy potentiation upon combined treatment with the xenobiotic dichloroacetate, for which the mitochondrial pyruvate dehydrogenase complex is 3 of 33 the main pharmacological target. The authors aimed to evaluate the immunoexpression of GLUT1 (glucose transporter 1), HK2 (hexokinase 2), PFKL (phosphofructokinase, liver type), PKM2 (pyruvate kinase M2), LDHA (lactate dehydrogenase A), and pPDH (phospho-pyruvate dehydrogenase) on different compartments of UBC tissue samples (normoxic versus hypoxic regions, stromal compartment, and blood vessels), further studying the functional effects of 2-deoxyD-glucose (2-DG . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.